Study reveals children's tumors resist immunotherapies due to lower inflammation and fewer mutations.

Researchers found that children's tumors are less inflammatory and have fewer mutations, making them less foreign to the immune system and reducing the effectiveness of current immunotherapies like checkpoint inhibitors. This study, analyzing 191 children aged 0 to 18, could lead to more tailored immunotherapies for pediatric cancer patients, focusing on stimulating immune cells against tumors from the start. Tracking immune responses could also help in adjusting treatments for individual patients.

2 months ago
8 Articles